Recombinant Anti-CD20 x Anti-CD22 Bispecific Antibody (scFv-Fc) is formed by fusing two different scFv fragments to the hinge and Fc regions, in which the Fc region are engineered by KIH. Two of scFv moiety has the antibody variable domain of either anti-CD20 specificity or anti-CD22 specificity, which produces bivalent IgG-like molecules with desired characteristics of intact antibodies. This BsAb is designed for the research of Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease therapy.
scFv-based Bispecific Fragments
FuncS; Promising therapeutic agent
Lymphoma; Leukemia; Antoimmune disease; Immune dysfunction disease
MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1
CD22; CD22 molecule; Cluster of differentiation 22; SIGLEC2; SIGLEC-2; B-cell receptor CD22; BL-CAM; CD22 antigen; T-cell surface antigen Leu-14; B-lymphocyte cell adhesion molecule; sialic acid binding Ig-like lectin 2; sialic acid-binding Ig-like lectin 2
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Welcome! For price inquiries, we will get back to you as soon as possible.
To order, please email